Abstract
Objective We investigated whether particular immunoglobulin GM (γ marker) alleles—individually or epistatically with a known human leukocyte antigen (HLA) risk allele—were associated with the development of Alzheimer disease (AD).
Methods Using a prospective cohort study design, we genotyped DNA samples from 209 African American (AA) and 638 European American (EA) participants for IgG1 (GM 3 and GM 17), IgG2 (GM 23+ and GM 23−), and HLA-DRB1 rs9271192 (A/C) alleles by TaqMan and rhAMP genotyping assays.
Results In EA subjects, none of the GM or HLA alleles—individually or epistatically—were associated with time to development of AD. In AA subjects, GM and HLA alleles individually were not associated with time to development of AD. However, there was a significant interaction: In the presence of GM 3 (i.e., GM 3/3 and GM 3/17 subjects), the presence of the HLA-C allele was associated with a 4-fold increase in the likelihood of developing AD compared with its absence (hazard ratio [HR] 4.17, 95% CI, 1.28–13.58). In the absence of GM 3 (GM 17/17 subjects), however, the presence of the HLA-C allele was not associated with time to development of AD (HR 1.10, 95% CI, 0.50–2.41).
Conclusions These results show that particular GM and HLA alleles epistatically contribute to the development of AD.
Glossary
- AA=
- African American;
- AD=
- Alzheimer disease;
- EA=
- European American;
- GWAS=
- Genome-wide association study;
- HR=
- hazard ratio;
- IGHG=
- immunoglobulin heavy chain G
Late-onset Alzheimer disease (AD) is a heritable, complex, and progressive brain disorder. Genome-wide association studies (GWAS) have identified numerous risk genes, but most of the heritability of AD remains unexplained, suggesting additional genes in its etiology. Many risk-conferring genes identified thus far are enriched in the immune system pathways.1 A major gene of the immune system—HLA-DRB1—has been associated with AD by many studies, including the largest GWAS of AD to date.2 The C allele of single-nucleotide polymorphism (SNP) rs9271192 within HLA-DRB1 seems to be a strong risk factor for AD.3
The current GWAS of AD do not evaluate a major gene complex of the immune system—GM (γ marker) allotypes encoded by immunoglobulin heavy chain G (IGHG) genes on chromosome 14.4,5 The 3 IGHG genes that encode GM allotypes are highly homologous and apparently not amenable to high throughput genotyping technology used in GWAS. Therefore, a candidate gene approach is necessary to investigate the role of the immunoglobulin GM allotypes in the immunobiology of AD. There is a good rationale for the GM gene involvement in the etiopathogenesis of AD. These genes have been shown to influence the magnitude of antibody responses to various antigens.4,5 The presence of amyloid-β (Aβ) plaques is one of the hallmarks of AD. IgG heavy chains, where all GM allotypes are expressed, have inherent antiamyloidogenic activity.6 Thus, polymorphic GM genes could contribute to the interindividual differences in the level of antibody responses to Aβ, thereby influencing the pathogenesis of the disease.
In this study, we aimed to determine the individual and/or epistatic (defined as modification of the action of a gene by an allele at another locus) contribution of GM and HLA-DRB1 genotypes to the development of AD.
Methods
Study Design and Samples
Using a prospective cohort study design, this investigation used archived DNA specimens and data from 3 longitudinal cohorts on aging: The Minority Aging Research Study, The Rush Memory and Aging Project, and The Religious Orders Study, which have been described in detail elsewhere.7,8
A stratified sampling scheme was used to select a subset of participants without dementia at baseline from each cohort. African American (AA) participants from all 3 studies were included (n = 209). A subset of European American (EA) participants was randomly selected from the 2 cohorts that are predominantly EA (N = 638).
Standard Protocol Approvals, Registrations, and Patient Consents
The study was approved by Institutional Review Boards of Rush University Medical Center and Medical University of South Carolina. All participants signed an informed consent and a repository consent to allow their data to be repurposed.
Data Availability
Data can be requested at radc.rush.edu.
GM Genotyping
IgG1 markers GM 3 and 17 (arginine to lysine) and IgG2 markers GM 23- and 23+ (valine to methionine) were determined by a TaqMan genotyping assay from Applied Biosystems Inc.
HLA-DRB1 rs9271192 Genotyping
HLA-DRB1 SNP rs9271192 (A > C) was determined by a custom-designed rhAMP SNP genotyping assay from Integrated DNA Technologies Inc.
Statistical Analysis
Multivariable logistic regression was used to compare rates of AD and mortality during follow-up between EAs and AAs, while adjusting for baseline age and length of follow-up time. Associations between the candidate genes and time to development of AD were assessed using Cox proportional hazards (PH) models, which accounted for mortality and loss to follow up. Models were developed separately for EAs and AAs, given that the allelic frequencies for GM and HLA vary considerably by race. Time to development of AD was modeled as a function of covariates (baseline age, sex, years of education, and APOE-4 carrier status), the candidate genes, and gene × gene interactions using a backwards model selection process. The covariates were forced into each model, regardless of statistical significance. For all models, the proportionality assumption was verified. No adjustment was made for multiple comparisons because this was largely a hypothesis generating exercise. Analyses were further stratified by sex to determine whether our findings were consistent for men and women. Analyses were conducted using SAS v9.4 (SAS Institute, Cary, NC).
Results
Table presents the descriptive statistics of EA and AA subjects. The proportion of subjects that developed AD during the follow-up was higher in EA than that in the AA group (37.3 vs 19.6%), although this was not significant after adjusting for baseline age and length of follow-up time, which was higher among EAs than AAs (mean [SD]: 12.5 [4.6] vs 10.4 [3.1], p < 0.05). In addition, a higher proportion of EA than AA subjects died during the follow-up (61.4 vs 30.0%). For all genes of interest, there were markedly different genotype distributions noted when comparing EAs to AAs (p < 0.05 for all comparisons).
Descriptive Statistics of Cohorts Stratified by Race
In EA subjects, none of the GM or HLA alleles—individually or epistatically—were associated with time to development of AD (all p-values > 0.10). In AA subjects, however, a different pattern emerged. When no gene by gene interactions were considered, GM and HLA alleles individually were not associated with time to development of AD. However, when we included their interaction in the model, we identified a robust interaction. In the presence of GM 3 (i.e., GM 3/3 and GM 3/17 subjects), the presence of the HLA-C allele was associated with a 4-fold increase in the likelihood of developing AD compared with its absence (hazard ratio [HR] 4.17, 95% CI, 1.28–13.58, figure 1). In the absence of GM 3 (GM 17/17 subjects), however, the presence of the HLA-C allele was not associated with time to development of AD (HR 1.10, 95% CI, 0.50–2.41, figure 2). Because the APOE-4 allele and other variables were used as covariates in these analyses, the interactive effect of GM and HLA genotypes on the development of AD was independent of the APOE-4 allele status and other subject covariates.
.
Discussion
The results presented here clearly show that in AA, the C allele of the rs9271192 SNP within HLA-DRB1 may be a strong risk factor for AD in presence of the immunoglobulin GM 3 allele. This association was not found for EA. As mentioned earlier, several studies have reported the association of the C allele of the HLA-DRB1 SNP with susceptibility to AD. Because none of these studies genotyped for the GM gene complex, it is not possible to determine whether the HLA associations observed were independent of the GM genotype status of the subjects.
A possible mechanism of joint GM-HLA gene involvement in susceptibility to AD could be through their putative influence on antibody responses to Aβ via HLA-DRB1-restricted antigen processing/presentation pathway. IgG heavy chains (which express GM allotypes) have been shown to have natural antiamyloidogenic properties.6 It is possible that the antigen presenting B cells with the membrane-bound IgG expressing the GM 3 allotype are not effective recognition structures for the Aβ peptides. Furthermore, these peptides may not fit properly in the peptide-binding groove of the at-risk HLA-DRB1 C allele, leading to inadequate presentation to the CD4+ T helper cells and the consequent lack of B cell activation to generate anti-Aβ antibodies.
The reasons for the observed racial differences in the contribution of GM and HLA alleles in the development of AD are not clear. Both GM and HLA allele frequencies differ significantly between AA and EA populations. These differences, together with other racially associated genetic and nongenetic factors relevant to the development of AD, may have contributed to the differences observed in this investigation.
Although the phenomenon of epistasis has been known for over 100 years,9 there is a paucity of studies to detect possible epistatic interactions in human diseases.10 It is hoped that results presented here will inspire further investigations on gene-gene interactions in AD and other complex polygenic/multifactorial diseases.
Study Funding
This work was supported in part by the NIH (NIA grant Nos. AG058489, AG10161, AG17917, AG22018, and NCATS grant No. UL1-TR001450).
Disclosure
Disclosures available: Neurology.org/NG.
Appendix Authors
Footnotes
Go to Neurology.org/NG for full disclosures. Funding information is provided at the end of the article.
The Article Processing Charge was funded by the authors.
- Received July 15, 2020.
- Accepted in final form December 22, 2020.
- Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
Letters: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.